

Journal Pre-proof



Cerebral infarcts, edema, hypoperfusion and vasospasm in preeclampsia and eclampsia

Lina BERGMAN, MD, PhD, Daniel HANNSBERGER, MD, Sonja SCHELL, RN, Henrik IMBERG, PhD, Eduard LANGENEGGER, MD, PhD, Ashley MOODLEY, MD, Richard PITCHER, MD, PhD, Stephanie GRIFFITH-RICHARDS, MD, Owen HERROCK, PhD, Roxanne HASTIE, PhD, Susan P. WALKER, MBBS, MD, Stephen TONG, MBBS, PhD, Johan WIKSTRÖM, MD, PhD, Catherine CLUVER, MD, PhD

PII: S0002-9378(24)01106-2

DOI: <https://doi.org/10.1016/j.ajog.2024.10.034>

Reference: YMOB 15904

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 14 August 2024

Revised Date: 22 October 2024

Accepted Date: 22 October 2024

Please cite this article as: BERGMAN L, HANNSBERGER D, SCHELL S, IMBERG H, LANGENEGGER E, MOODLEY A, PITCHER R, GRIFFITH-RICHARDS S, HERROCK O, HASTIE R, WALKER SP, TONG S, WIKSTRÖM J, CLUVER C, Cerebral infarcts, edema, hypoperfusion and vasospasm in preeclampsia and eclampsia, *American Journal of Obstetrics and Gynecology* (2024), doi: <https://doi.org/10.1016/j.ajog.2024.10.034>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 The Author(s). Published by Elsevier Inc.

1 Cerebral infarcts, edema, hypoperfusion and vasospasm in preeclampsia and
2 eclampsia

3
4 Lina BERGMAN, MD, PhD¹⁻³, Daniel HANNSBERGER, MD⁴, Sonja SCHELL, RN¹,
5 Henrik IMBERG, PhD^{5,6}, Eduard LANGENEGGER, MD, PhD¹, Ashley MOODLEY, MD¹,
6 Richard PITCHER, MD, PhD⁷, Stephanie GRIFFITH-RICHARDS, MD⁷, Owen HERROCK,
7 PhD³, Roxanne HASTIE, PhD^{8,9} Susan P WALKER, MBBS, MD^{8,9}, Stephen TONG,
8 MBBS, PhD^{8,9}, Johan WIKSTRÖM, MD, PhD*⁴, Catherine CLUVER, MD, PhD*^{1,8,9}

9
10 ¹Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa

11 ²Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

12 ³Department of Obstetrics and Gynecology, Institute of clinical sciences, Sahlgrenska Academy, University of Gothenburg,
13 Gothenburg, Sweden

14 ⁴Department of Surgical Sciences, Neuroradiology Uppsala University, Uppsala, Sweden

15 ⁵Statistiska Konsultgruppen, Gothenburg, Sweden

16 ⁶Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg,
17 Gothenburg, Sweden

18 ⁷Division of Radiodiagnosis, Stellenbosch University, Cape Town, South Africa

19 ⁸Translational Obstetrics Group, Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia

20 ⁹Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia

21 *Denotes equal contribution

22
23 *Conflicts of interest*

24 The authors report no conflict of interest.

25
26 *Acknowledgements of financial support*

27 The study was funded by the Swedish Medical Society, Märta Lundqvist foundation, Swedish
28 foundation for international cooperation in research and higher education (STINT), Jane and

29 Dan Olssons foundation, Mercy Perinatal foundation, the Swedish Research Council (VR),
30 Center for clinical research Dalarna and the Preeclampsia foundation. LB is a Wallenberg
31 Scholar, supported by the Wallenberg Center for Molecular and Translational Medicine
32 (WCMTM). CC receives salary support from the Mercy Health Foundation and the Swedish
33 Research Council.

34

35 *Corresponding author:*

36 Lina Bergman

37 Department of Obstetrics and Gynecology

38 PO Kvinnokliniken SU Östra

39 SE 416 85 Göteborg, Sweden

40 Telephone number 0046707920780

41 Email: lina.bergman@obgyn.gu.se

42

43 *Word count*

44 Word Count Abstract: 356

45 Word Count Main Text: 3182

46

47 *Registration:*

48 PROVE database and biobank registration number: ISRCTN1062344

49

50 TWEETABLE STATEMENT

51 Preeclampsia and in particular eclampsia are associated with cerebral infarcts, cerebral
52 edema, decreased cerebral perfusion and vasospasm.

53

54 SHORT TITLE

55 Pathophysiology of eclampsia

56

57 AJOG AT A GLANCE

58 *Why was this study conducted?*

59 Eclampsia has previously been associated with infarctions on conventional magnetic
60 resonance imaging (MRI). This needs verification in larger prospective studies.

61 Advanced MRI techniques including cerebral diffusion (shows subclinical edema), perfusion
62 (capillary blood flow) and angiography can increase the understanding of underlying
63 pathophysiology of eclampsia.

64

65 *What are the key findings?*

66 Eclampsia was associated with cerebral infarcts, increased diffusion, hypoperfusion and
67 vasospasm.

68

69 *What does this study add to what is already known?*

70 Our data provide evidence against hyperperfusion of cerebral arteries, previously thought to
71 cause cerebral edema in eclampsia. Rather, women with eclampsia seem to suffer from
72 insufficient cerebral perfusion. This is important knowledge to guide future interventions for
73 neuroprotection. In addition, we provide robust evidence of presence of cerebral infarcts,
74 causing potential irreversible injury after eclampsia.

75

76 ABSTRACT

77 **Background**

78 Eclampsia, a serious pregnancy complication, is associated with cerebral edema and
79 infarctions but the underlying pathophysiology remains largely unexplored.

80 **Objectives**

81 To assess the pathophysiology of eclampsia using specialized magnetic resonance imaging
82 that measures diffusion, perfusion, and vasospasm.

83 **Study design**

84 This was a cross-sectional study recruiting consecutive pregnant women between April 2018
85 to November 2021 at Tygerberg Hospital, Cape Town, South Africa. We recruited women
86 with eclampsia, preeclampsia, and normotensive pregnancies who underwent magnetic
87 resonance imaging after birth. Main outcome measures were cerebral infarcts, edema, and
88 perfusion using intravoxel incoherent motion imaging and vasospasm using magnetic
89 resonance imaging angiography. The imaging protocol was established before inclusion.

90 **Results**

91 Forty-nine women with eclampsia, 20 with preeclampsia and 10 normotensive women were
92 included. Cerebral infarcts were identified in 34% of eclamptic, 5% of preeclamptic (risk
93 difference (RD) 0.29; 95% confidence interval (CI) 0.06 to 0.52, $p=0.012$) and in no
94 normotensive controls. Eclamptic women were more likely to have vasogenic cerebral edema
95 compared to preeclamptic (80% vs 20%, RD 0.60; CI 0.34 to 0.85, $p<.001$) and normotensive
96 women (RD 0.80; CI 0.47 to 1.00, $p<.001$). Diffusion was increased in eclampsia in the
97 parietooccipital white matter (mean difference (MD) $0.02 \times 10^{-3} \text{ mm}^2/\text{s}$, CI 0.00 to 0.05,
98 $p=0.045$) and the caudate nucleus (MD $0.02 \times 10^{-3} \text{ mm}^2/\text{s}$, CI 0.00 to 0.04, $p=0.033$) when
99 compared to preeclamptic women. Diffusion was also increased in eclamptic women in the
100 frontal (MD $0.07 \times 10^{-3} \text{ mm}^2/\text{s}$, CI 0.02 to 0.12, $p=0.012$) and parietooccipital white matter

101 (MD $0.05 \times 10^{-3} \text{ mm}^2/\text{s}$, CI 0.02 to 0.07, $p=0.03$) and the caudate nucleus (MD 0.04×10^{-3}
102 mm^2/s , CI 0.00 to 0.07, $p=0.028$) when compared to normotensive women. Perfusion was
103 decreased in edematous regions. Hypoperfusion was present in the caudate nucleus in
104 eclampsia (MD $-0.17 \times 10^{-3} \text{ mm}^2/\text{s}$, CI -0.27 to -0.06, $p=0.003$) when compared to
105 preeclampsia. There were no signs of hyperperfusion. Vasospasm was present in 18% of
106 eclamptic, 6% of preeclamptic and none of the controls.

107 **Conclusions**

108 Eclampsia is associated with cerebral infarcts, vasogenic cerebral edema, vasospasm and
109 decreased perfusion, all not usually evident on standard clinical imaging. This may explain
110 why some have cerebral symptoms and signs despite having normal conventional imaging.

111 *Keywords*

112 Eclampsia, preeclampsia, pathophysiology, hypoperfusion, vasospasm, hyperperfusion
113
114

115 INTRODUCTION

116 Preeclampsia, a life-threatening complication of pregnancy, occurs when a woman develops
117 hypertension with end-organ injury in the second half of pregnancy.¹ One of the most feared
118 complications of preeclampsia is eclampsia. Eclampsia presents with generalized tonic-clonic
119 seizures and is associated with cerebral edema in 71-80% of cases.²⁻⁴ The etiology is largely
120 unknown and there is no directed treatment.

121

122 Cerebral edema can be visualized on both computerized tomography scan and conventional
123 magnetic resonance imaging (MRI). It is defined as an increase in brain water content.

124 Common etiologies are cytotoxic (direct cell injury and swelling), vasogenic (blood brain
125 barrier injury), osmotic (changes in osmolality in plasma or interstitium) or interstitial
126 (increased ventricular pressure). Diffusion-weighted imaging (DWI), is a MRI technique
127 based on differences in random Brownian motion of water molecules between different
128 tissues. This permits separation of vasogenic from cytotoxic edema.

129

130 Advanced MRI techniques can be used to assess cerebral diffusion, perfusion and vessel
131 vasospasm and could be used to further understand the etiology of edema. Intravoxel
132 incoherent imaging (IVIM), is an advanced DWI technique, which enables the extraction of
133 both water diffusion and capillary perfusion.⁵ If cerebral water diffusion is raised, it indicates
134 increased brain water content. Cerebral perfusion can be measured by utilizing the IVIM
135 technique by visualizing blood microcirculation in capillary networks of cerebral tissue.⁵⁻⁷ A
136 decreased perfusion indicates insufficient blood flow to a region. To measure vasospasm, 3D
137 Time-of-flight MR angiography is utilized.

138

139 Cerebral diffusion, perfusion and vasospasm have not been studied in preeclampsia and
140 eclampsia. If affected, it may explain the occurrence of neurological signs and symptoms in
141 women with preeclampsia and eclampsia who do not have evidence of pathology on
142 conventional MRI. It could also offer important insights into the pathophysiology of
143 eclampsia, directing future research.⁸ We therefore used these advanced MRI techniques to
144 study women with eclampsia, preeclampsia and normotensive controls.

145

146 MATERIALS AND METHODS

147 *Study cohort*

148 This cross-sectional prospective study, included women recruited to the Preeclampsia
149 Obstetric Adverse Events (PROVE) biobank at Tygerberg Hospital, Cape Town, South
150 Africa.⁹ Tygerberg is the largest referral hospital in the Western Cape Province, with over
151 8,500 high-risk deliveries a year.⁹

152

153 Women were prospectively included after a diagnosis of eclampsia or preeclampsia or at
154 admission for delivery for controls. MRI was performed postpartum before discharge after
155 birth. We included women who did not have a clinical indication for imaging, such as a
156 suspicion of stroke. Women with known neurological or cardiac disease were ineligible. For
157 normotensive women, additional exclusion criteria included chronic hypertension and
158 diabetes mellitus. Baseline data were obtained by interview and extraction from medical
159 records. Women were followed up until discharge. Data were recorded on a Research
160 Electronic Data Capture database¹⁰ and double checked for accuracy.

161

162 *Exposures*

163 Preeclampsia was defined according to the American College of Obstetricians and
164 Gynecologists Practice Bulletin but significant proteinuria was also required (protein
165 creatinine ratio ≥ 30 mg/mmol (0.3 mg/mg) or ≥ 0.3 g protein in a 24 hour urine collection or
166 urine dipstick $>1+$ on more than one occasion).¹¹ We only included women with preeclampsia
167 with severe features according to the same classification. This approach was used to
168 distinguish eclampsia as an organ-specific complication to preeclampsia with other severe
169 features.

170 Eclampsia was defined as generalized tonic-clonic seizures in a woman with preeclampsia in
171 the absence of another etiology. We subdivided eclampsia into eclampsia only (one eclamptic
172 seizure with no other neurological symptoms) or complex eclampsia (women who had
173 multiple seizures, Glasgow Coma Scale < 13 or eclampsia together with other organ
174 complications).

175
176 Pulmonary edema was diagnosed when there was worsening dyspnea, fine bibasal inspiratory
177 crackles on auscultation and features of pulmonary edema on chest x-ray. Hemolysis, elevated
178 liver enzymes and low platelets syndrome was defined as a platelet count $< 100 \times 10^9/L$,
179 aspartate aminotransferase > 70 U/L, and hemolysis (lactate dehydrogenase > 600 U/L or
180 hemolysis on a peripheral blood smear). Renal impairment was defined as a serum creatinine
181 >120 $\mu\text{mol/L}$ which is higher than the ACOG definition. Severe hypertension was defined as
182 a blood pressure ≥ 160 mm Hg systolic and/or a diastolic blood pressure ≥ 110 mm Hg.

183

184 *Outcomes measures*

185 MRI was performed at 1.5T (Aera, Siemens Healthcare, Erlangen, Germany). The protocol
186 included sagittal 2DT1 weighted spin echo, axial 2DT2 weighted spin echo, axial 2DT2
187 weighted gradient echo, axial 2D fluid attenuated inversion recovery, and axial diffusion

188 weighted sequences. The DWI was acquired with nine b-values for separation of diffusion
189 and perfusion parameters, using IVIM.⁵ All assessors were blinded to clinical exposures.

190 Of the outcomes in our study, only cerebral edema (vasogenic and cytotoxic) can be
191 visualized on a conventional MRI protocol.

192

193 Acute cerebral infarcts were defined as high intensity lesions on the b₁₀₀₀ DWI with
194 corresponding low intensity on the Apparent Diffusion Coefficient (ADC) maps. Vasogenic
195 cerebral edema was defined as high intensity white matter lesions on Fluent Attenuated
196 Inversion Recovery (FLAIR) and ADC images, and low signal on DWI. Edema volume was
197 calculated by adding the areas of edema in individual slices, multiplied with slice thickness.

198

199 The IVIM parametric maps (D, D* and f) were calculated from multi b-value DWI sequence
200 using commercially available software (Olea Sphere 3.0, Olea Medical, La Ciotat, France).

201 These metrics correspond to the rate of water self-diffusion (D), which relates to tissue water
202 content, pseudo-diffusion related to capillary blood flow velocity (D*), and volume fraction
203 of perfused capillaries (f).⁵ D, D* and f were measured in the frontal white matter, the
204 parietooccipital white matter, the caudate nucleus, the lentiform nucleus, and the thalamus.

205 Estimates were obtained from averages of the right and left sides in two or three slices. The
206 same measurements were obtained from regions of edema, when present.

207 Cerebral diffusion was defined as the diffusion coefficient, and used as a sign of subclinical
208 edema. Cerebral perfusion was assessed using pseudodiffusion and perfusion fraction,
209 yielding the combined perfusion estimate, which correlates with the tissue capillary blood
210 flow.⁵

211

212 Vasospasm was defined as a vessel segment with more than a 50% diameter reduction, as
213 compared with adjacent normal appearing vessels and was evaluated on the 3D Time-of-flight
214 MR angiography. The first and second segments of the anterior and posterior, and first
215 segment of middle cerebral arteries were analyzed. As this assessment is subjective,
216 independent evaluations were performed by both a radiologist and a neuroradiologist who
217 were blinded to clinical data. Segments in which both readers detected more than 50%
218 diameter reduction were assigned positive for vasospasm, not including hypoplastic segments
219 of the first segments of the anterior and posterior cerebral arteries.

220

221 Further description of MRI sequences parameters can be found in **Supplemental Table 1**.

222

223 *Statistical methods*

224 Descriptive data are presented as means with standard deviations or medians with
225 interquartile ranges for numeric variables, and as numbers with percentages for categorical
226 variables. Binary variables were analyzed using the Farrington-Manning test for the risk
227 difference between groups. Numeric variables were analyzed using Welch's T-test,
228 accounting for unequal variances between groups. Results are presented as mean difference
229 (MD) with 95% confidence intervals. Differences in diffusion and perfusion in edema regions
230 vs parieto-occipital white matter were evaluated using paired T-test. Evaluations in subgroups
231 with few observations ($n < 6$) were performed using non-parametric permutation tests and
232 corresponding confidence intervals were calculated by test inversion. Positively skewed
233 variables were log-transformed prior to analysis and the fold-change between groups
234 calculated by exponentiating the mean difference on log scale. All statistical tests were
235 performed at the 5% significance level. Statistical analyses were performed using

236 SAS/STAT[®] Software, Version 9.4 of the SAS System for Windows (SAS Institute Inc.,
237 Cary, NC, USA).

238

239 *Sample size*

240 Previous studies found a large variation in presence of cerebral infarcts on MRI.^{2,3,12} We
241 aimed for a sample size of 50 women with eclampsia, 20 with preeclampsia, and 10
242 normotensive controls to be able to detect a difference in cerebral ischemia between groups.
243 This is similar to other larger prospective studies.^{2,3}

244

245 *Ethics approval and registration details*

246 Ethics approval was obtained from Stellenbosch University Health Research Ethics
247 Committee (protocol number N18/03/034, Federal Wide assurance number 00001372,
248 Institutional Review Board number IRB0005239). All participants or their guardians signed
249 informed consent. The biobank is registered (ISRCTN10623443) and the protocol is
250 published.⁹

251

252 *Data availability*

253 Anonymized data is available on request after approval by the corresponding author.

254

255 RESULTS

256 *Participants*

257 Eighty-one women had MRI examinations between April 2018 and November 2021. The
258 median (range) time from delivery to MRI was 3 (1–6) days for women with preeclampsia
259 and 1 (0–13) days for women with eclampsia. Twelve (60%) women with preeclampsia and
260 10 (20%) women with eclampsia had MRI performed more than 48 hours after delivery. Two

261 women had clinically evident strokes and were excluded. Forty-nine women had eclampsia,
262 20 had preeclampsia without eclampsia and 10 had a normotensive pregnancy (**Figure 1**).
263 During the study period, 101 women with eclampsia were included in the PROVE biobank.
264 Most common reason for not performing an MRI was unavailability of the MRI. There were
265 no major differences in background characteristics between women who underwent an MRI
266 and those who did not (**Supplemental table 2**).

267

268 *Maternal characteristics and pregnancy outcomes*

269 Background data can be found in **Table 1**. Women with preeclampsia and eclampsia were
270 more often nulliparous, less likely to have attended antenatal care and more likely to
271 experience a stillbirth compared to normotensive pregnancies. Women who experienced
272 eclampsia were also more likely to use alcohol and smoke cigarettes during pregnancy (**Table**
273 **1**). All women with preeclampsia and eclampsia were treated with antihypertensive
274 medication. All women with preeclampsia had one or more severe features; seventeen women
275 had severe hypertension, 11 women had pulmonary edema, six women experienced HELLP-
276 syndrome and six women had renal impairment. One woman with preeclampsia only had
277 headache as a severe feature. Chronic hypertension occurred in five (25%) of women with
278 preeclampsia and two (4%) of women with eclampsia (**Table 1**).

279

280 *Cerebral infarcts*

281 Sixteen (34%) women in the eclampsia group had cerebral infarcts compared to one (5%) in
282 the preeclampsia group (risk difference 0.29; 95% CI 0.06 to 0.52, $p=0.012$) and none (0%) in
283 the normotensive group (risk difference 0.34; 95% CI 0.03 to 0.65, $p=0.030$). (**Table 2**,
284 **Figure 2**)

285

286 *Vasogenic cerebral edema*

287 In the eclampsia group, 39 (80%) had vasogenic cerebral edema on MRI compared with 4
288 (20%) in the preeclampsia (risk difference 0.60; 95% CI 0.34 to 0.85, $p < .001$) and none (0%)
289 in the normotensive group (risk difference 0.80; 95% CI 0.47 to 1.00, $p < .001$) (**Table 2**,
290 **Figure 2**). When vasogenic cerebral edema was present, women with eclampsia had a larger
291 volume of edema compared with women with preeclampsia, presented in **Figure 3** (fold
292 change 12.2; 95% CI 3.51 to 42.7, $p < .001$).

293 Systemic blood pressure was not associated with cerebral edema ($p = 0.99$ for severe
294 hypertension and $p = 0.51$ for chronic hypertension).

295

296 *Diffusion (subclinical cerebral edema)*

297 Women with eclampsia had increased diffusion in frontal white matter (MD $0.07 \times 10^{-3} \text{ mm}^2/\text{s}$;
298 95% CI 0.02 to 0.12, $p = 0.012$), the parietooccipital white matter (MD $0.05 \times 10^{-3} \text{ mm}^2/\text{s}$; 95%
299 CI 0.02 to 0.07, $p = 0.003$) and the caudate nucleus (MD $0.04 \times 10^{-3} \text{ mm}^2/\text{s}$; 95% CI 0.00 to
300 0.07, $p = 0.028$) compared to women with normotensive pregnancies (**Table 3**). Women with
301 preeclampsia had increased diffusion estimates in the frontal white matter (MD 0.07×10^{-3}
302 mm^2/s ; 95% CI 0.00 to 0.14, $p = 0.048$), and a tendency for increased diffusion in both the
303 parietooccipital white matter (MD $0.02 \times 10^{-3} \text{ mm}^2/\text{s}$; 95% CI -0.01 to 0.05, $p = 0.12$) and
304 caudate nucleus regions (MD $0.02 \times 10^{-3} \text{ mm}^2/\text{s}$; 95% CI -0.01 to 0.05, $p = 0.25$) compared to
305 women with normotensive pregnancies (**Table 3, Figure 4**).

306 Women with eclampsia had increased diffusion in parietooccipital white matter (MD 0.02
307 $\times 10^{-3} \text{ mm}^2/\text{s}$; 95% CI 0.00 to 0.05, $p = 0.045$) and caudate nucleus regions (MD 0.02×10^{-3}
308 mm^2/s ; 95% CI 0.00 to 0.04, $p = 0.033$) when compared to those with preeclampsia (**Table 3**).

309

310 *Perfusion*

311 Women with eclampsia had decreased perfusion in the caudate nucleus compared to women
312 with preeclampsia (mean difference $-0.17 \times 10^{-3} \text{ mm}^2/\text{s}$, 95% CI -0.27 to -0.06, $p=0.003$)
313 (**Table 3, Figure 4**). There were no significant differences between women who had
314 experienced eclampsia and normotensive controls.

315

316 *Vasospasm*

317 Vasospasm was present in eight (18%) with eclampsia compared to one (5.6%) with
318 preeclampsia (risk difference 0.13; 95% CI -0.07 to 0.32, $p=0.20$) and none (0%) in the
319 normotensive group (risk difference 0.18; 95% CI -0.06 to 0.43, $p=0.14$) (**Table 2, Figure 4**).

320

321 *Diffusion and perfusion in women with cerebral edema*

322 In women with cerebral edema visible on conventional MRI, we compared women with
323 eclampsia to preeclampsia. There was a tendency for lower perfusion in the eclampsia group
324 when compared to those with preeclampsia (fold change 0.57, 95% CI 0.26 to 1.33, $p=0.19$)
325 (**Table 4**). When comparing edema regions to normal appearing parieto-occipital white
326 matter, there was an increase in water diffusion (MD $0.68 \text{ mm}^2/\text{s} \times 10^{-3}$; 95% CI 0.59 to 0.76,
327 $p<.001$) and reduction of perfusion (MD $-1.00 \text{ mm}^2/\text{s} \times 10^{-3}$; 95% CI -1.09 to -0.91, $p<.001$) in
328 edema regions (**Table 5**).

329

330 *MRI findings in women with complex eclampsia*

331 Women with only one eclamptic seizure and no other end-organ involvement were compared
332 to women with complex eclampsia (multiple seizures and/or additional neurological
333 symptoms and/or other organ complications). There were no significant differences in the
334 prevalence of cerebral infarcts (6/20 [30%] vs 10/29 [37%], $p=0.61$) or vasogenic cerebral

335 edema (15/20 [75%] vs 24/29 [83%], $p=0.51$) between the groups. Also, there were no
336 differences in the prevalence of vasospasm (4/29 [15%] vs 4/20 [22%], $p=0.56$).

337

338 There were no differences in diffusion or perfusion when women with complex eclampsia
339 were compared to women with eclampsia without additional complications (**Supplemental**
340 **Table 3**).

341

342 COMMENT

343 *Principal findings*

344 Cerebral infarcts and edema are common in women who experienced eclampsia. Increased
345 diffusion (subclinical edema) was observed in several regions in eclamptic women compared
346 to normotensive women and women with preeclampsia. Hyperperfusion was not identified in
347 eclampsia and preeclampsia. In contrast, certain areas showed decreased cerebral capillary
348 blood flow, especially when associated with cerebral edema. Vasospasm was present in one in
349 five women with eclampsia.

350 Preeclampsia with severe features does not have similar pathology as eclampsia and cerebral
351 infarcts and vasospasm is uncommon. Approximately one of five women with severe
352 preeclampsia have cerebral edema.

353 *Results in context of what is known*

354 Previously, it was thought that eclampsia was reversible and not associated with long term
355 complications. We, and others have now shown that cerebral infarcts are common in
356 eclampsia which might be potentially irreversible.^{2,3,12} Interestingly, women who experience
357 only one seizure without other end-organ involvement have a similar risk of cerebral infarcts
358 to those who have experienced multiple seizures or eclampsia with other end-organ

359 involvement. Imaging and ongoing neurological follow up may be warranted for all who have
360 experienced eclampsia.

361

362

363 Cerebral edema is common in eclampsia, affecting 80% of women in this cohort. Cerebral
364 diffusion (subclinical cerebral edema) was also increased in women with eclampsia, likely
365 reflecting an increase in microscopic tissue water content in this group. Our study is the first
366 to evaluate diffusion in eclampsia and this could be important for understanding the
367 pathophysiology of eclampsia.

368

369 Our data show that eclampsia is associated with hypoperfusion and not hyperperfusion,
370 particularly in areas with cerebral edema. It is therefore unlikely that forced cerebral capillary
371 vessel dilatation and hyperperfusion play a role in the development of eclampsia. Notably, the
372 caudate nucleus is particularly affected by hypoperfusion in this South African cohort. This is
373 in accordance with our previous results showing hypoperfusion of the caudate nucleus in
374 preeclampsia compared to normotensive controls in a Swedish cohort.¹³

375

376 Vasospasm has been studied in some older case-reports or series of women with eclampsia
377 and preeclampsia.¹⁴⁻¹⁶ In some, vasospasm was found in several women with eclampsia and
378 preeclampsia and resolved with resolution of cerebral edema. In others, vasospasm was not
379 present.^{17,18} These discrepancies may be due to differences in imaging technique and criteria
380 for vasospasm and timing of imaging, as this is likely a dynamic process. Our results, from
381 the largest prospectively included cohort of women with eclampsia and preeclampsia, support
382 the presence of vasospasm in eclampsia.

383

384 *Research implications*

385 Women with eclampsia who have cerebral infarcts may have an even higher risk of
386 developing longer term neurological sequelae than women without infarcts and should be
387 followed up in future research.

388 If cerebral perfusion is decreased in eclampsia, it is important to evaluate the effects of
389 antihypertensive and neuroprotective treatments on cerebral blood flow. The effect of acute
390 decreases in systemic blood pressure on cerebral autoregulation and subsequent perfusion has
391 not been studied.

392

393 *Clinical implications*

394 Conventional imaging does not rule out cerebral pathology in women who have experienced
395 eclampsia and preeclampsia.

396 Women who have experienced preeclampsia and eclampsia may have an increased risk of
397 neurological long-term sequelae such as epilepsy, cognitive decline, and dementia in this
398 population irrespective of normal conventional imaging.¹⁹⁻²¹ Long term follow up and
399 education about the potential consequences of eclampsia may be needed.

400 Women presenting with neurological signs and symptoms who undergo a normal
401 conventional MRI brain imaging may still have pre-clinical brain edema and perfusion
402 defects.

403

404 *Strengths and Limitations*

405 This is the first study of women with eclampsia undergoing MRI imaging using a protocol to
406 assess diffusion, perfusion and vasospasm. We present novel findings of pre-clinical edema,
407 perfusion deficits and vasospasm in eclampsia and preeclampsia. MRI examinations were
408 performed in women who did not qualify for clinically indicated imaging in our setting.

409 Women with a suspicion of stroke were not included. The study was prospectively
410 conducted, and MRI sequences were interpreted by blinded neuroradiologists.
411 The study has limitations. All imaging was performed after the onset of complications. It is
412 therefore not possible to draw conclusions around factors present before the development of
413 eclampsia. For the perfusion estimates, lack of differences between groups could be due to the
414 relatively low magnetic field and use of the IVIM technique for perfusion estimates, thereby
415 decreasing the signal-to-noise ratio. However, an important advantage is that IVIM does not
416 require contrast agent administration, which is why we chose to use it in this study. This
417 allowed for antepartum measurements if needed and also allowed imaging in cases of where
418 renal lesions where contrast agent administration for research would be ethically questioned.
419 Thus, repeating the MRI investigation with higher field strength and/or contrast agent based
420 perfusion measurements could be of value.
421 Ideally, we would want to image women before an eclamptic seizure to evaluate whether
422 edema is present and precedes eclampsia. This is extremely challenging as eclampsia is
423 unpredictable and MRI examinations are expensive and not readily available, particularly in
424 settings where eclampsia is common.

425

426 *Conclusions*

427 Cerebral infarcts were present in one third of women who experienced eclampsia,
428 independent of disease severity. Women with preeclampsia and in particular eclampsia have
429 pre-clinical cerebral edema (increased diffusion). This may explain neurological signs and
430 symptoms in these women when there is no clinically evident cerebral edema on conventional
431 MRI. Hyperperfusion with forced capillary dilatation does not seem to be the underlying
432 cause of edema in eclampsia. Vasospasm with decreased capillary blood flow (hypoperfusion)
433 is more likely to contribute to cerebral edema formation and subsequent neuroinflammation in

434 preeclampsia and eclampsia. A conventional MRI does not rule out pathology in preeclampsia
435 and eclampsia.

436

437 ACKNOWLEDGMENTS

438 We thank the women who were willing to be enrolled, the staff at Tygerberg Hospital and
439 Stellenbosch University for their support.

Journal Pre-proof

440

441 REFERENCES

- 442 1. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. *Lancet*.
443 2021;398(10297):341-354.
- 444 2. Verma AK, Garg RK, Pradeep Y, et al. Posterior encephalopathy syndrome in women
445 with eclampsia: Predictors and outcome. *Pregnancy Hypertens*. 2017;10:74-82.
- 446 3. Junewar V, Verma R, Sankhwar PL, et al. Neuroimaging features and predictors of
447 outcome in eclamptic encephalopathy: a prospective observational study. *AJNR*.
448 *American journal of neuroradiology*. 2014;35(9):1728-1734.
- 449 4. Mai H, Liang Z, Chen Z, et al. MRI characteristics of brain edema in
450 preeclampsia/eclampsia patients with posterior reversible encephalopathy syndrome.
451 *BMC pregnancy and childbirth*. 2021;21(1):669.
- 452 5. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M.
453 Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.
454 *Radiology*. 1988;168(2):497-505.
- 455 6. Tunlayadechanont P, Panyaping T, Chansakul T, Hirunpat P, Kampaengtup A.
456 Intravoxel incoherent motion for differentiating residual/recurrent tumor from post-
457 treatment change in patients with high-grade glioma. *Neuroradiol J*. 2023;36(6):657-
458 664.
- 459 7. Takahashi T, Uwano I, Akamatsu Y, et al. Prediction of cerebral hyperperfusion
460 following carotid endarterectomy using intravoxel incoherent motion magnetic
461 resonance imaging. *Journal of stroke and cerebrovascular diseases : the official*
462 *journal of National Stroke Association*. 2023;32(2):106909.

- 463 8. Bergman L, Torres-Vergara P, Penny J, et al. Investigating Maternal Brain Alterations
464 in Preeclampsia: the Need for a Multidisciplinary Effort. *Current hypertension*
465 *reports*. 2019;21(9):72.
- 466 9. Bergman L, Bergman K, Langenegger E, et al. PROVE-Pre-Eclampsia Obstetric
467 Adverse Events: Establishment of a Biobank and Database for Pre-Eclampsia. *Cells*.
468 2021;10(4).
- 469 10. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an
470 international community of software platform partners. *J Biomed Inform*.
471 2019;95:103208.
- 472 11. Gynecologists ACoOa. Gestational Hypertension and Preeclampsia: ACOG Practice
473 Bulletin, Number 222. *Obstet Gynecol*. 2020;135(6):e237-e260.
- 474 12. Dahiya K, Rohilla S, Agarwal K, Rathod M, Dahiya A. MRI Brain Lesions in
475 Eclampsia: A Series of 50 Cases Admitted to HDU of a Tertiary Care Hospital. *J*
476 *Family Reprod Health*. 2018;12(1):51-56.
- 477 13. Nelander M, Hannsberger D, Sundstrom-Poromaa I, et al. Assessment of cerebral
478 perfusion and edema in preeclampsia with intravoxel incoherent motion MRI. *Acta*
479 *obstetrica et gynecologica Scandinavica*. 2018;97(10):1212-1218.
- 480 14. Tsukimori K, Ochi H, Yumoto Y, et al. Reversible posterior encephalopathy
481 syndrome followed by MR angiography-documented cerebral vasospasm in
482 preeclampsia-eclampsia: report of 2 cases. *Cerebrovasc Dis*. 2008;25(4):377-380.
- 483 15. Harscher S, Witte OW, Moller U, Bloos G, Pfleiderer SO, Terborg C. [Cerebral
484 vasospasms with hemodynamic infarctions as a complication of HELLP syndrome].
485 *Nervenarzt*. 2003;74(12):1122-1126.
- 486 16. Kobayashi T, Tokunaga N, Isoda H, Kanayama N, Terao T. Vasospasms are
487 characteristic in cases with eclampsia/preeclampsia and HELLP syndrome: proposal

- 488 of an angiospastic syndrome of pregnancy. *Semin Thromb Hemost.* 2001;27(2):131-
489 135.
- 490 17. Takeuchi M, Matsuzaki K, Harada M, Nishitani H, Matsuda T. Cerebral
491 hyperperfusion in a patient with eclampsia with perfusion-weighted magnetic
492 resonance imaging. *Radiat Med.* 2005;23(5):376-379.
- 493 18. Morriss MC, Twickler DM, Hatab MR, Clarke GD, Peshock RM, Cunningham FG.
494 Cerebral blood flow and cranial magnetic resonance imaging in eclampsia and severe
495 preeclampsia. *Obstet Gynecol.* 1997;89(4):561-568.
- 496 19. Nerenberg KA, Park AL, Vigod SN, et al. Long-term Risk of a Seizure Disorder After
497 Eclampsia. *Obstet Gynecol.* 2017;130(6):1327-1333.
- 498 20. Basit S, Wohlfahrt J, Boyd HA. Pre-eclampsia and risk of dementia later in life:
499 nationwide cohort study. *BMJ.* 2018;363:k4109.
- 500 21. Aukes AM, Wessel I, Dubois AM, Aarnoudse JG, Zeeman GG. Self-reported
501 cognitive functioning in formerly eclamptic women. *Am J Obstet Gynecol.*
502 2007;197(4):365 e361-366.

503

Journal Pre-proof

505 **Table 1.** Baseline characteristics of the study cohort.

	Normotensive (n=10)	Preeclampsia* (n=20)	Eclampsia (n=49)
Demographics and baseline characteristics			
Age (years), mean (SD)	29.5 (6.1)	28.7 (7.7)	22.4 (5.6)
Body mass index (kg/m ²), mean (SD)**	30.0 (6.9)	28.2 (7.6)	24.8 (5.6)
Nulliparous	2 (20%)	8 (40%)	36 (74%)
Any antenatal care	9 (90%)	18 (90%)	41 (84%)
HIV positive	1 (10%)	3 (15%)	6 (12%)
Smoking during pregnancy	2 (20%)	2 (10%)	9 (18%)
Alcohol use during pregnancy	0 (0%)	0 (0%)	7 (14%)
Diabetes mellitus	0 (0%)	0 (0%)	0 (0%)
Chronic hypertension	0 (0%)	5 (26%)	2 (4%)
Mode of birth: vaginal	1 (10%)	6 (30%)	17 (35%)
elective or non-urgent CS	6 (60%)	2 (10%)	1 (2%)
emergency CS	3 (30%)	12 (60%)	31 (63%)
Gestation at delivery (weeks and days), median (range)	38+6 (27+3–41+3)	32+6 (21+2–36+1)	34+4 (24+2–40+5)
Antihypertensive medication at time of birth	0 (0)	20 (100%)	49 (100%)
Liveborn infant	9 (90%)	14 (70%)	41 (84%)
Birthweight (g), mean (SD)	2729 (842)	1559 (584)	2076 (946)
Maternal complications			
Maternal death	0 (0%)	0 (0%)	0 (0%)
Intensive care unit admission	0 (0%)	1 (5%)	4 (8%)
Eclampsia	0 (0%)	0 (0%)	49 (100%)
Recurrent eclampsia	0 (0%)	0 (0%)	17 (35%)
Intracranial hemorrhage	0 (0%)	0 (0%)	1 (2%)
Glasgow Coma Scale < 13	0 (0%)	0 (0%)	12 (24%)
Cortical blindness	0 (0%)	2 (10%)	2 (4%)
Pulmonary edema	0 (0%)	11 (55%)	1 (2%)
Inotropic support	0 (0%)	1 (5%)	1 (2%)
Renal impairment	0 (0%)	6 (30%)	10 (20%)
Dialysis	0 (0%)	1 (5%)	1 (2%)
HELLP syndrome	0 (0%)	6 (30%)	14 (29%)
Disseminated Intravascular Coagulation (INR >1.2)	0 (0%)	1 (5%)	5 (10%)

Severe hypertension	0 (0%)	17 (85%)	17 (35%)
Sepsis	0 (0%)	3 (15%)	4 (8%)
Venous thromboembolism	0 (0%)	0 (0%)	1 (2%)
Placental abruption	1 (10%)	2 (10%)	3 (6%)
<p>Data are presented as mean (SD) or median (range) for numeric variables, and as numbers and percentages for categorical variables.</p> <p>*All women had preeclampsia with severe features</p> <p>**Data on body mass index is missing for 2 (20%) women in the control group, 8 (40%) of women with preeclampsia, and 24 (49%) of women with eclampsia.</p> <p>Abbreviations: CS, caesarean section; DIC, disseminated intravascular coagulation; HELLP, hemolysis, elevated liver enzymes, low platelets; HIV, human immunodeficiency virus; INR, international normalized ratio; IQR, interquartile range; SD, standard deviation.</p>			

506

507 **Table 2.** Vasogenic cerebral edema, infarcts and vasospasm in normotensive women

508 (controls) and in women with preeclampsia or eclampsia.

509

Variable	Normotensive (n=10)	Preeclampsia (n=20)	Eclampsia (n=49)	Risk difference (95% CI)		
				Eclampsia vs Preeclampsia	Eclampsia vs Normotensive	Preeclampsia vs Normotensive
Cerebral infarcts	0 (0%)	1 (5.0%)	16 (34%)	0.29 (0.06 to 0.52) p=0.012	0.34 (0.03 to 0.65) p=0.030	0.05 (-0.09 to 0.19) p=0.47
Vasogenic cerebral edema	0 (0%)	4 (20%)	39 (80%)	0.60 (0.34 to 0.85) p<.001	0.80 (0.47 to 1.00) p<.001	0.20 (-0.06 to 0.46) p=0.13
Vasospasm*	0 (0%)	1 (5.6%)	8 (18%)	0.13 (-0.07 to 0.32) p=0.20	0.18 (-0.06 to 0.43) p=0.14	0.06 (-0.09 to 0.20) p=0.45
Numbers (percentages) are presented.						
Comparisons between groups were performed using the Farrington-Manning test for the risk difference.						
*Data on vasospasm missing for n=2 women in the preeclampsia group and n=5 women in the eclampsia group.						

510

511 **Table 3.** Diffusion and perfusion in normotensive women and in women with preeclampsia or eclampsia.

Variable	Normotensive (n=10)	Preeclampsia (n=20)	Eclampsia (n=49)	Mean difference (95% CI)		
				Eclampsia vs Normotensive	Preeclampsia vs Normotensive	Eclampsia vs Preeclampsia
Diffusion (D, mm²/s x10⁻³)						
Frontal white matter	0.70 (0.06)	0.77 (0.11)	0.77 (0.08)	0.07 (0.02 to 0.12) p=0.012	0.07 (0.00 to 0.14) p=0.048	-0.00 (-0.06 to 0.06) p=0.95
Parietooccipital white matter	0.65 (0.03)	0.67 (0.03)	0.70 (0.06)	0.05 (0.02 to 0.07) p=0.003	0.02 (-0.01 to 0.05) p=0.12	0.02 (0.00 to 0.05) p=0.045
Caudate nucleus	0.67 (0.04)	0.68 (0.03)	0.70 (0.04)	0.04 (0.00 to 0.07) p=0.028	0.02 (-0.01 to 0.05) p=0.25	0.02 (0.00 to 0.04) p=0.033
Lentiform nucleus	0.67 (0.03)	0.68 (0.03)	0.69 (0.05)	0.02 (-0.01 to 0.04) p=0.15	0.01 (-0.01 to 0.04) p=0.34	0.01 (-0.01 to 0.03) p=0.47
Thalamus	0.65 (0.02)	0.67 (0.03)	0.67 (0.02)	0.02 (-0.00 to 0.03) p=0.093	0.01 (-0.01 to 0.03) p=0.33	0.01 (-0.01 to 0.02) p=0.51
Perfusion (fxD*, mm²/s x10⁻³)						

Frontal white matter	1.42 (0.44)	1.19 (0.37)	1.23 (0.33)	-0.19 (-0.51 to 0.14) p=0.23	-0.22 (-0.57 to 0.12) p=0.19	0.04 (-0.17 to 0.24) p=0.73
Parietooccipital white matter	1.23 (0.14)	1.29 (0.17)	1.23 (0.16)	-0.00 (-0.11 to 0.10) p=0.96	0.06 (-0.06 to 0.18) p=0.33	-0.06 (-0.16 to 0.03) p=0.19
Caudate nucleus	1.11 (0.29)	1.32 (0.18)	1.15 (0.22)	0.04 (-0.18 to 0.25) p=0.72	0.20 (-0.02 to 0.42) p=0.067	-0.17 (-0.27 to -0.06) p=0.003
Lentiform nucleus	1.54 (0.35)	1.46 (0.21)	1.38 (0.21)	-0.16 (-0.42 to 0.10) p=0.19	-0.08 (-0.34 to 0.18) p=0.52	-0.08 (-0.20 to 0.04) p=0.18
Thalamus	1.34 (0.17)	1.42 (0.11)	1.38 (0.16)	0.03 (-0.09 to 0.16) p=0.59	0.07 (-0.05 to 0.20) p=0.23	-0.04 (-0.11 to 0.03) p=0.23
Data are presented as mean and standard deviation.						
Comparisons between groups were performed using Welch's T-test, accounting for unequal variances between groups.						

513 **Table 4.** Diffusion and perfusion in edema regions, in women with preeclampsia compared to
 514 eclampsia.

Variable	Eclampsia (n=32)	Preeclampsia (n=3)	Fold change (95% CI)	p-value
Diffusion (D, mm ² /s x10 ⁻³)	1.30 (1.2–1.6)	1.40 (1.2–1.4)	1.02 (0.81 to 1.26)	0.81
Perfusion (fxD*, mm ² /s x10 ⁻³)	0.17 (0.1–0.3)	0.36 (0.3–0.4)	0.57 (0.26 to 1.33)	0.19

Data are presented as median and interquartile range.

Data were missing for one woman in the preeclampsia groups and seven women in the eclampsia group.

Comparison between groups were performed using non-parametric permutation test for the mean difference on log-transformed variables. Corresponding confidence intervals were calculated by test inversion.

Abbreviations: CI, confidence interval.

515

516

517

518 **Table 5.** Diffusion and perfusion in edema regions versus parietooccipital white matter
 519 without edema in 35 women with cerebral edema.

Variable	Edema regions	Parietooccipital white matter	Mean difference (95% CI)	p-value
Diffusion (D, mm ² /s x10 ⁻³)	1.38 (0.24)	0.70 (0.05)	0.68 (0.59 to 0.76)	<.001
Perfusion (fxD*, mm ² /s x10 ⁻³)	0.25 (0.18)	1.25 (0.17)	-1.00 (-1.09 to -0.91)	<.001

Descriptive data are presented as mean (SD).

Data to calculate diffusion and perfusion in edema regions missing for n=1 women with preeclampsia and n=7 women with eclampsia.

Statistical analyses were performed using paired T-test.

Abbreviations: CI, confidence interval; SD, standard deviation.

520

521


522 **Figure legends**


523 **Figure 1.** Flow chart of the study cohort, showing the number of women included in the
524 biobank, who underwent MRI, and that had analyzed data.


525 **Figure 2.** MRI demonstrating subcortical vasogenic cerebral edema in bilateral parietal lobes
526 (a; FLAIR sequence), with scattered small areas of ischemia (arrows) (b; diffusion weighted
527 sequence, c; ADC map) in a woman who experienced eclampsia. A smaller area of
528 subcortical edema in a woman with preeclampsia (without eclampsia) is observed in the left
529 parietal lobe (d; FLAIR image), without ischemic lesions (e; diffusion weighted sequence, f;
530 ADC map). Corresponding FLAIR (g) and diffusion weighted image (h) and ADC map (i)
531 from a normotensive control show normal findings.

532 **Figure 3.** Box and scatter plot of edema volume in women with eclampsia and preeclampsia.
533 Points are observed values. The box limits are the lower and upper quartiles. The line within
534 the box represents the median and the diamond represents the mean. Box plot not shown in
535 the preeclampsia group due to small sample size.


536 **Figure 4.** MRI images of cerebral arteries (a, e), diffusion (b, f) and perfusion (c,d, g,h) in a
537 woman with eclampsia (a–d) and a normotensive control (e–h). MR images from a woman
538 with eclampsia show vasospasm (arrow in a), increased water diffusion (D) (b) and low
539 perfusion estimates (pseudodiffusion, D^* in c, and perfusion fraction, f in d) in areas with
540 edema.







Journal Pre-proof



Supplemental Table 1. MRI sequence parameters.

Sequence	Type	Orientation	Spatial resolution (mm)	TR (ms)/TE (ms)/flip angle (degree)	Number of excitations
T1 weighted	2D turbo spin echo	sagittal	0.6 x 0.6 x 4	389/9.7/150	3
T2 weighted	2D turbo spin echo	axial	0.6 x 0.6 x 4	5720/80/150	3
T2* weighted	2D gradient echo	axial	0.4 x 0.4 x 4	830/25/20	1
FLAIR	2D IR-spin echo	axial	0.7 x 0.7 x 4	8000/84/150	1
Diffusion weighted	2D echo planar imaging	axial	1.25 x 1.25 x 3	6500/119/90	1
MR angiography	3D time-of-flight	axial	0.4 x 0.4 x 0.5	27/7/25	1

MRI was performed on 1.5T (Aera, Siemens Healthcare, Erlangen, Germany). The examination protocol included sagittal 2DT1 weighted spin echo, axial 2DT2 spin echo, axial 2DT2 gradient echo, axial 2DFLAIR and axial diffusion weighted (DWI). The DWI sequence was acquired with nine b-values (0, 50, 100, 150, 200, 400, 600, 800, and 1000 s/mm² x 10⁻³) for separation of diffusion and perfusion parameters.

Assessment of edema, ischemia, diffusion, and perfusion were performed by a blinded radiologist (DH). Vasogenic edema was evaluated on FLAIR images and quantified by manual outlining on individual slices. Edema volume was calculated as the sum of these areas multiplied by slice thickness.

The presence of ischemic lesions was assessed on the b₁₀₀₀ DWI images, where high signal intensity corresponding to cytotoxic edema was interpreted as a sign of acute ischemia.

The intravoxel incoherent imaging parametric maps (D, D* and f) were calculated from the multi b-value DWI sequence using commercially available software (Olea Sphere 3.0, Olea Medical, La Ciotat, France). These metrics correspond to the degree of water self-diffusion (D), pseudo-diffusion related to capillary blood flow (D*), and volume fraction of perfused capillaries (f) as described by Le Bihan.⁹ D, D* and f were measured in the following regions: frontal white matter, parietooccipital white matter, caudate nucleus, lentiform nucleus, and thalamus. Estimates were obtained from averages of right and left sides in two or three slices.

Supplemental Table 2. Characteristics of women with eclampsia with and without MRI in the database.

Variable	With MRI (n=49)	Without MRI (n=52)
Demographics and baseline characteristics		
Age (years), mean (SD)	22.4 (5.6)	22.6 (6.3)
Body mass index (kg/m ²), mean (SD)	24.8 (5.6)	28.6 (7.6)
Nulliparous	36 (73.5%)	32 (61.5%)
Any antenatal care	41 (83.7%)	42 (80.4%)
HIV positive	6 (12.2%)	6 (11.5%)
Smoking during pregnancy	9 (18.4%)	4 (7.7%)
Alcohol use during pregnancy	7 (14.3%)	2 (3.8%)
Gestational diabetes mellitus	0 (0.0%)	1 (1.9%)
Chronic hypertension	2 (4.2%)	3 (5.8%)
Mode of birth		
Vaginal	17 (34.7%)	12 (23.1%)
Elective or non-urgent Cesarean section	1 (2.0%)	0 (0.0%)
Emergency Cesarean section	31 (63.3%)	39 (75.0%)
Gestation at delivery (weeks and days), median (range)	34+4 (24+2–40+5)	34+2 (23+0–41+6)
Liveborn infant	41 (83.7%)	42 (82.4%)
Birthweight (g), mean (SD)	2076 (946)	2125 (914)
Maternal complications		
Maternal death	0 (0.0%)	3 (5.8%)
Intensive care unit admission	4 (8.2%)	6 (11.5%)
Recurrent eclampsia	17 (34.7%)	17 (32.7%)
Glasgow Coma Scale <13	12 (24.5%)	9 (17.3%)
Cortical blindness	2 (4.1%)	3 (5.8%)
Pulmonary edema	1 (2.0%)	3 (5.8%)
Inotropic support	1 (2.0%)	2 (3.8%)
Renal impairment	10 (20.4%)	4 (7.7%)
Dialysis	1 (2.0%)	0 (0.0%)
HELLP syndrome	14 (28.6%)	10 (19.2%)
DIC INR >1.2	10 (20.4%)	1 (1.9%)
Severe hypertension	17 (34.7%)	20 (38.5%)
Sepsis	4 (8.2%)	5 (9.6%)
Venous thromboembolism	1 (2.0%)	1 (1.9%)
Placental abruption	3 (6.1%)	2 (3.8%)
Data are presented as mean (SD) or median (range) for numeric variables, and as number (percent) for categorical variables.		
Abbreviations: DIC, disseminated intravascular coagulation; HELLP, hemolysis, elevated liver enzymes, low platelets; HIV, human immunodeficiency virus; INR, international normalized ratio; SD, standard deviation.		

Supplemental Table 3. MRI findings in women with eclampsia or eclampsia with complications.

Variable	Eclampsia with complications (n=29)	Eclampsia (n=20)	Mean difference (95% CI)	p-value
Diffusion (D, mm²/s x10⁻³)				
Frontal white matter	0.78 (0.10)	0.76 (0.06)	0.02 (-0.03 to 0.07)	0.46
Parietooccipital white matter	0.70 (0.06)	0.70 (0.05)	0.01 (-0.03 to 0.04)	0.74
Caudate nucleus	0.71 (0.04)	0.69 (0.03)	0.02 (-0.01 to 0.04)	0.19
Lentiform nucleus	0.69 (0.06)	0.68 (0.04)	0.01 (-0.02 to 0.04)	0.36
Thalamus	0.67 (0.03)	0.67 (0.02)	-0.00 (-0.02 to 0.01)	0.68
Perfusion (fxD*, mm²/s x10⁻³)				
Frontal white matter	1.21 (0.28)	1.25 (0.40)	-0.05 (-0.26 to 0.17)	0.67
Parietooccipital white matter	1.24 (0.16)	1.21 (0.18)	0.03 (-0.07 to 0.13)	0.56
Caudate nucleus	1.10 (0.24)	1.21 (0.19)	-0.11 (-0.24 to 0.02)	0.097
Lentiform nucleus	1.37 (0.20)	1.39 (0.23)	-0.03 (-0.16 to 0.10)	0.68
Thalamus	1.36 (0.19)	1.40 (0.11)	-0.04 (-0.13 to 0.05)	0.38
Data are presented as mean and standard deviation. Statistical analyses were performed using Welch's T-test.				